BBIO
BridgeBio Pharma Inc
$
61.980
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
64.190
Open
62.740
VWAP
61.88
Vol
2.14M
Mkt Cap
11.94B
Low
60.790
Amount
132.23M
EV/EBITDA(TTM)
--
Total Shares
187.13M
EV
14.12B
EV/OCF(TTM)
--
P/S(TTM)
33.73
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
151.94M
+2483.22%
-0.672
-51.99%
169.09M
+44.98%
-0.644
-26.82%
196.37M
+77.61%
-0.537
-43.47%
Estimates Revision
The market is revising Upward the revenue expectations for BridgeBio Pharma, Inc. (BBIO) for FY2025, with the revenue forecasts being adjusted by 0.82% over the past three months. During the same period, the stock price has changed by 29.80%.
Revenue Estimates for FY2025
Revise Upward
+0.82%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+10.14%
In Past 3 Month
Stock Price
Go Up
+29.80%
In Past 3 Month
17 Analyst Rating
19.28% Upside
Wall Street analysts forecast BBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBIO is 73.93 USD with a low forecast of 57.00 USD and a high forecast of 98.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
0 Hold
0 Sell
Strong Buy
19.28% Upside
Current: 61.980
Low
57.00
Averages
73.93
High
98.00
19.28% Upside
Current: 61.980
Low
57.00
Averages
73.93
High
98.00
Goldman Sachs
Buy
upgrade
$55 -> $100
2025-10-31
New
Reason
Goldman Sachs
Price Target
$55 -> $100
2025-10-31
New
upgrade
Buy
Reason
Goldman Sachs raised the firm's price target on BridgeBio to $100 from $55 and keeps a Buy rating on the shares. BridgeBio's Q3 results highlighted strong commercial momentum for Attruby, with U.S. sales of $108.1M, exceeding estimates and reflecting a 40% increase in prescriptions since August, the analyst tells investors in a research note. Management cited growing share among newly diagnosed ATTR-CM patients and reiterated a 30%-35% target, supported by continued investment in awareness and diagnosis expansion. With topline results from the PROPEL 3 achondroplasia study expected in early 2026 and a deepening commercial pipeline, BridgeBio's transition toward a multi-product, profitable biotech remains on track, offering further upside potential, the firm says.
Oppenheimer
Oppenheimer
Outperform
upgrade
$73 -> $81
2025-10-30
New
Reason
Oppenheimer
Oppenheimer
Price Target
$73 -> $81
2025-10-30
New
upgrade
Outperform
Reason
Oppenheimer raised the firm's price target on BridgeBio to $81 from $73 and keeps an Outperform rating on the shares. The firm notes U.S. Attruby revenue of $108M surpassed its/Street's expectations of $106/95M. Ex-U.S. sales contributed $4.3M in royalty revenue. Oppenheimer says there could be some slight adherence headwinds developing over time as patients may come off drug without noticing benefit, though this is built into its $1B 2026 Attruby sales expectations. Shares may take a breather after this week's +13% move, but the firm remains Outperform-rated and would be buying into infigratinib's early 2026's readout.
TD Cowen
NULL -> Buy
upgrade
$60 -> $95
2025-10-30
New
Reason
TD Cowen
Price Target
$60 -> $95
2025-10-30
New
upgrade
NULL -> Buy
Reason
TD Cowen raised the firm's price target on BridgeBio to $95 from $60 and keeps a Buy rating on the shares. The firm said the 51% quarter-over-quarter Attruby sales growth beat expectations and was driven by treatment naive patients and accelerating new patient prescriptions. BridgeBio remains focused on the Attruby launch and the late-stage pipeline and is two-for-two so far with positive LGMD and ADH1 readouts set to be released.
Truist
NULL -> Buy
upgrade
$66 -> $80
2025-10-30
New
Reason
Truist
Price Target
$66 -> $80
2025-10-30
New
upgrade
NULL -> Buy
Reason
Truist raised the firm's price target on BridgeBio to $80 from $66 and keeps a Buy rating on the shares. The firm has updated its model to reflect Attruby performance in Q3, positive Phase 3 data in ribitol in LGMD2I/R9, and positive Phase 3 data in encaleret in ADH1, the analyst tells investors in a research note.
Piper Sandler
Overweight
maintain
$93 -> $98
2025-10-30
New
Reason
Piper Sandler
Price Target
$93 -> $98
2025-10-30
New
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on BridgeBio to $98 from $93 and keeps an Overweight rating on the shares. The firm notes the company reported their Q3 earnings after the close, which included Attruby sales of $108.1M for the quarter, ahead of consensus of $102.4M and its estimate of $93M. While the investor bar remains high, Piper is encouraged by the steady increase in Attruby sales throughout its first year of the launch and continues to believe that it can be a market leader in the ATTRCM space.
H.C. Wainwright
Buy
maintain
$80 -> $90
2025-10-29
Reason
H.C. Wainwright
Price Target
$80 -> $90
2025-10-29
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on BridgeBio to $90 from $80 and keeps a Buy rating on the shares. The company reported positive results from its Phase 3 study of encaleret in autosomal dominant hypocalcemia type 1, the analyst tells investors in a research note. The firm upped its probability of approval to 90% from 80% and believes encaleret could be submitted for approval to the FDA during the first half of 2026 with market entry either in late 2026 or early 2027.
See All Ratings
Valuation Metrics
The current forward P/E ratio for BridgeBio Pharma Inc (BBIO.O) is -27.40, compared to its 5-year average forward P/E of -9.20. For a more detailed relative valuation and DCF analysis to assess BridgeBio Pharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-9.20
Current PE
-27.40
Overvalued PE
-4.00
Undervalued PE
-14.41
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-13.64
Current EV/EBITDA
-57.24
Overvalued EV/EBITDA
-5.89
Undervalued EV/EBITDA
-21.40
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
86.73
Current PS
62.64
Overvalued PS
161.43
Undervalued PS
12.04
Financials
Annual
Quarterly
FY2025Q3
YoY :
+4318.01%
120.70M
Total Revenue
FY2025Q3
YoY :
-27.13%
-136.36M
Operating Profit
FY2025Q3
YoY :
+12.59%
-184.94M
Net Income after Tax
FY2025Q3
YoY :
+10.47%
-0.95
EPS - Diluted
FY2025Q3
YoY :
-38.32%
-112.44M
Free Cash Flow
FY2025Q3
YoY :
+21.06%
94.56
Gross Profit Margin - %
FY2025Q3
YoY :
-19.39%
-168.92
FCF Margin - %
FY2025Q3
YoY :
-97.45%
-153.22
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 118.22% over the last month.
Sold
0-3
Months
25.8M
USD
7
3-6
Months
184.9M
USD
16
6-9
Months
417.3M
USD
11
0-12
Months
135.3M
USD
8
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
6.0M
Volume
1
6-9
Months
3.1M
Volume
1
0-12
Months
258.4K
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
7
5.3M
Volume
Months
0-12
3
1.1M
Volume
Months
Congress Trading
Congress areBuying! The buying amount has increased100%over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
2
16.0K
USD
Months
3-6
1
8.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 118.22% over the last month.
Sold
0-3
Months
25.8M
USD
7
3-6
Months
184.9M
USD
16
6-9
Months
417.3M
USD
11
0-12
Months
135.3M
USD
8
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BBIO News & Events
Events Timeline
2025-10-29 (ET)
2025-10-29
16:08:03
BridgeBio announces Q3 earnings per share of 95 cents, surpassing consensus estimate of 78 cents.
2025-10-29
07:15:26
BridgeBio reports successful achievement of primary endpoint in Phase 3 study of encaleret.
2025-10-27 (ET)
2025-10-27
07:09:22
BridgeBio announces findings from Phase 3 FORTIFY trial of BBP-418
Sign Up For More Events
Sign Up For More Events
News
6.5
11-03MarketWatchBiotech Makes a Comeback: Reasons to Add These Rising Stocks to Your Portfolio Today.
1.0
11-03NewsfilterBridgeBio to Showcase Data on Overall ATTR-CM Variant and V142I (V122I) Groups from ATTRibute-CM at AHA Scientific Sessions 2025
6.0
11-03BenzingaHC Wainwright & Co. Affirms Buy Rating for BridgeBio Pharma, Keeps $90 Price Target Intact
Sign Up For More News
People Also Watch
CRK
Comstock Resources Inc
19.230
USD
+2.56%
ESI
Element Solutions Inc
27.120
USD
+1.50%
FAF
First American Financial Corp
62.140
USD
-0.59%
COTY
Coty Inc
3.900
USD
-1.76%
OSK
Oshkosh Corp
121.320
USD
-1.60%
POST
Post Holdings Inc
105.780
USD
+1.78%
GNTX
Gentex Corp
23.290
USD
-0.68%
LNTH
Lantheus Holdings Inc
56.820
USD
-1.51%
BMI
Badger Meter Inc
181.930
USD
+0.82%
JOBY
Joby Aviation Inc
16.320
USD
-5.88%
FAQ
What is BridgeBio Pharma Inc (BBIO) stock price today?
The current price of BBIO is 61.98 USD — it has decreased -1.05 % in the last trading day.
What is BridgeBio Pharma Inc (BBIO)'s business?
What is the price predicton of BBIO Stock?
What is BridgeBio Pharma Inc (BBIO)'s revenue for the last quarter?
What is BridgeBio Pharma Inc (BBIO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for BridgeBio Pharma Inc (BBIO)'s fundamentals?
How many employees does BridgeBio Pharma Inc (BBIO). have?